"Double 11" Concludes: Record-Breaking Sales Data from Tmall and JD.com

「双 11」收官：天猫京东数据创新高

This year's "Double 11" concluded without major e-commerce platforms releasing GMV figures.
今年「双 11」结束后，各大电商平台未公布 GMV 相关数据。

According to Tmall, by midnight on November 11, 402 brands had reached sales exceeding 100 million yuan, with 243 of them being domestic brands.
天猫表示，截至 11 月 11 日零点，共有 402 个品牌成交额破亿，其中 243 个是国货品牌。

Around 38,000 brands experienced year-over-year sales growth of over 100%.
约 3.8 万个品牌的成交额同比增长超过 100%。

Tmall's total users surpassed 800 million, while the 88VIP user count reached 32 million.
天猫的全周期访问用户数突破 8 亿，88VIP 用户数也达 3200 万。

JD.com also reported record-breaking sales and order volume for this year's Double 11 by 11:59 PM on November 11.
京东同样在 11 月 11 日晚表示今年「双 11」成交额和订单量创新高，销售表现强劲。

Over 60 brands had sales exceeding 1 billion yuan, with nearly 20,000 brands achieving a threefold increase in sales compared to the previous year.
超过 60 个品牌销售额破 10 亿，接近 2 万个品牌同比增长超 3 倍。

China Air Show: Global Debut of the Twin-Seat J-20S Stealth Fighter

中国航展：歼-20S双座战机全球首次亮相

At the China Air Show, the twin-seat J-20S stealth fighter made its global debut, attracting significant attention.
中国航展上，歼-20S 双座隐身战机首次公开亮相，引发广泛关注。

The aircraft features a tandem twin-seat design, with a larger cockpit than the single-seat version, enhancing tactical coordination capabilities.
该战机采用串联双座设计，驾驶舱比单座版更大，增强了战术协同能力。

Developed by the Aviation Industry Corporation of China, the J-20S is a new-generation twin-seat stealth fighter with air-to-ground and air-to-sea strike capabilities.
歼-20S 是由航空工业集团自主研发的新一代双座隐身战机，具备对地、对海打击和制空能力。

The fighter can serve as a "battlefield commander" to coordinate with other manned and unmanned aircraft in combat.
该战机还能作为“战场指挥官”，协调其他战机和无人机作战。

With its strong situational awareness and tactical command capabilities, the J-20S is well-suited for the future informationized battlefield.
其强大的态势感知能力和战术控制能力，更适合未来信息化战场。

Experts believe that the J-20S could transform combat strategies, further enhancing the combat capabilities of the air force.
专家分析指出，歼-20S 可能会改变作战模式，进一步提升空军战力。

Musk: Tesla Improves Optimus Robot Design for Mass Production

马斯克：特斯拉改进 Optimus 机器人设计以实现量产

Tesla CEO Elon Musk revealed that the company is working on optimizing the design of the Optimus robot to address production bottlenecks.
特斯拉 CEO 马斯克透露，公司正致力于改进 Optimus 机器人的设计，以解决生产瓶颈问题。

Optimus is considered one of Tesla's most exciting future products, with an estimated price between $20,000 and $30,000.
Optimus 被认为是特斯拉未来的核心产品之一，预计售价为 2 万至 3 万美元。

The robot is designed to be an ideal assistant for anyone in need, capable of handling various daily tasks.
该机器人定位于成为各类人群的理想助手，能满足多种日常需求。

Tesla is working to improve production processes, enhance design efficiency, and build a complex supply chain.
特斯拉正努力优化生产流程，提高设计效率并构建复杂的供应链。

Musk stated that these improvements will enable Optimus to achieve mass production with higher efficiency.
马斯克表示，通过这些改进，Optimus 将能以更高效率实现大规模生产。

The goal of mass production is to make the robot more affordable for a broader audience.
量产目标是为了让更多人能够负担得起这款机器人。

First Non-Viral CAR-T Therapy Approved for Treating Systemic Lupus Erythematosus

首个非病毒定点整合 CAR-T 疗法获批治疗系统性红斑狼疮

On November 5, Biotech company Bangyao Biotech announced that its non-viral PD1-targeted CAR-T product BRL-203 has been approved for clinical trials for treating systemic lupus erythematosus (SLE).
11 月 5 日，邦耀生物宣布其非病毒 PD1 定点整合 CAR-T 产品 BRL-203 获得临床试验批准，用于治疗系统性红斑狼疮。

The therapy is specifically designed for moderate-to-severe cases and is the world’s first CAR-T therapy for autoimmune diseases to receive IND approval.
该疗法专为中重度难治性系统性红斑狼疮患者研发，是全球首个获批 IND 的自免疾病 CAR-T 疗法。

This treatment has a cost advantage, potentially priced below 100,000 yuan, significantly lower than other CAR-T therapies on the market.
此疗法在成本上有优势，相比其他 CAR-T 细胞疗法价格或降至 10 万元以下。

BRL-203 can be prepared within just three days, reducing patient wait times significantly.
BRL-203 仅需 3 天即可制备完毕，显著减少患者的等待时间。

The development of autologous CAR-T therapies offers diversified treatment options for autoimmune diseases.
自体 CAR-T 疗法的发展使得自免疾病的治疗选择多样化。

Bangyao Biotech's innovative product provides a more economical treatment choice for patients.
邦耀生物的这一创新产品为患者提供了更为经济的治疗选择。